2.30Open2.30Pre Close0 Volume24 Open Interest2.00Strike Price0.00Turnover417.66%IV4.37%PremiumDec 20, 2024Expiry Date2.12Intrinsic Value100Multiplier19DDays to Expiry0.18Extrinsic Value100Contract SizeAmericanOptions Type0.8923Delta0.0474Gamma1.68Leverage Ratio-0.0196Theta0.0006Rho1.50Eff Leverage0.0017Vega
Geron Stock Discussion
Almost low enough
Geron Corp - Receives $250 Million at Closing, $125 Million in Debt Available
Royalty Pharma to Acquire Royalty Interest in Geron’s Rytelo for $125 Million
Achieved $28.2 million in RYTELO(TM) (imetelstat) net product revenue in first full quarter of sales
Received $250 million in gross proceeds from synthetic royalty and debt financings with Royalty Pharma and Pharmakon Advisors, with access to an additional $125 million in debt
No comment yet